Cellares Secures $327M, Revolutionizing Cell Therapy Manufacturing Globally
June 16, 2026, 9:39 pm
Location: United States, New Jersey, Lawrence
Employees: 10001+
Founded date: 1858
Cellares closed its Series D funding at $327 million, backed by ARK Invest, Prime Radiant Partners, and other major investors. This capital drives global expansion of its automated cell therapy manufacturing. The IDMO model and Smart Factories promise to industrialize advanced treatments, ensuring rapid, consistent production for hundreds of thousands of patients annually by 2027. An IPO is planned. Cellares tackles the critical challenge of scaling life-saving cell therapies for broad patient access.
Cellares has cemented its position as a transformative force in biotechnology. The company recently completed its Series D financing round. It raised a substantial $327 million. This significant capital infusion signals robust investor confidence. It targets the urgent need for scalable cell therapy manufacturing. This funding will accelerate Cellares' global mission. It aims to make advanced, life-saving treatments accessible to more patients.
The Series D round attracted a diverse group of prominent investors. ARK Invest joined the funding with a $20 million investment. Prime Radiant Partners added another $50 million. Other major participants include BlackRock, Eclipse, T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors. This strong financial support underscores Cellares’ innovative approach. It validates its potential to redefine therapeutic production.
Cellares operates as an Integrated Development and Manufacturing Organization (IDMO). This model streamlines the entire cell therapy production process. It integrates development, manufacturing, and quality control. The IDMO approach moves beyond traditional contract development and manufacturing organizations (CDMOs). It offers a vertically integrated solution. This integration ensures greater efficiency and reliability.
Cellares deploys fully automated platforms. The Cell Shuttle handles end-to-end cell therapy manufacturing. Cell Q manages automated in-process and release quality control. These platforms are central to Cellares' strategy. They eliminate manual variability. They boost process success rates. The Cell Shuttle notably received the FDA's Advanced Manufacturing Technology (AMT) designation. This recognition highlights its innovative design and potential impact. The system boasts a 100% automation success rate across numerous processes.
The science behind cell therapy is robust. The challenge lies in scaling production. Conventional methods are often manual and costly. They struggle to meet demand. Cellares addresses this bottleneck directly. Its automated platforms promise up to ten times more cell therapy batches. They achieve this at significantly reduced costs. This industrialization is crucial. It will unlock access for hundreds of thousands of patients.
Cellares has achieved critical milestones. The company successfully manufactured and delivered GMP (Good Manufacturing Practice) doses of rese-cel. This is Cabaletta Bio’s investigational CAR T cell therapy. The doses met all specifications. They were infused into patients on schedule. This demonstrated clinical validation of the Cell Shuttle platform.
Following this success, Cabaletta Bio signed a 10-year commercial supply agreement. This secures future manufacturing capacity with Cellares. Another monumental agreement stands with Bristol Myers Squibb. This $380 million global manufacturing deal reserves significant capacity. It spans facilities in the United States, Europe, and Japan. These partnerships confirm Cellares' technical and commercial prowess. They validate its role as a preferred manufacturing partner.
Cellares is rapidly expanding its global footprint. It operates IDMO Smart Factories in South San Francisco, California. Another facility is in Bridgewater, New Jersey. Further expansion is underway. New facilities are under development in Leiden, the Netherlands. Another is planned for Kashiwa City, Japan. This global network is strategic. It ensures consistent production standards worldwide. It provides drug sponsors with localized manufacturing capabilities.
The Leiden facility is particularly significant for European expansion. It will be GMP-ready in 2027. Prime Radiant Partners’ expertise in European pharma services will aid this growth. The goal is a truly global manufacturing infrastructure. This network will support commercial-scale production for hundreds of thousands of patients annually. This target is set for 2027.
The recent funding enables Cellares to accelerate its plans. The capital supports full commercial-scale operations. It also funds an anticipated Initial Public Offering (IPO) in 2027. This financial strategy positions Cellares for long-term growth. The company serves a range of cell therapy programs. These include CAR T, TCR-T, and progenitor T-cell therapies. Its partners include industry leaders like Bristol Myers Squibb and Cabaletta Bio. TScan Therapeutics and ProTgen also utilize Cellares platforms.
Cellares is transforming a specialized, complex process. It is making it industrial-scale, reliable, and affordable. This paradigm shift is essential for cell therapy's mainstream adoption. The company is building the infrastructure that modern medicine demands. Its vision of accessible, high-quality cell therapies is becoming reality. Cellares is a crucial player in the future of advanced therapeutic manufacturing. Its innovations promise to deliver life-saving treatments to a global patient population.
Cellares: Catalyzing Cell Therapy's Future
Cellares has cemented its position as a transformative force in biotechnology. The company recently completed its Series D financing round. It raised a substantial $327 million. This significant capital infusion signals robust investor confidence. It targets the urgent need for scalable cell therapy manufacturing. This funding will accelerate Cellares' global mission. It aims to make advanced, life-saving treatments accessible to more patients.
Investor Backing Fuels Innovation
The Series D round attracted a diverse group of prominent investors. ARK Invest joined the funding with a $20 million investment. Prime Radiant Partners added another $50 million. Other major participants include BlackRock, Eclipse, T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors. This strong financial support underscores Cellares’ innovative approach. It validates its potential to redefine therapeutic production.
The IDMO Model: A New Paradigm
Cellares operates as an Integrated Development and Manufacturing Organization (IDMO). This model streamlines the entire cell therapy production process. It integrates development, manufacturing, and quality control. The IDMO approach moves beyond traditional contract development and manufacturing organizations (CDMOs). It offers a vertically integrated solution. This integration ensures greater efficiency and reliability.
Automating Advanced Medicine
Cellares deploys fully automated platforms. The Cell Shuttle handles end-to-end cell therapy manufacturing. Cell Q manages automated in-process and release quality control. These platforms are central to Cellares' strategy. They eliminate manual variability. They boost process success rates. The Cell Shuttle notably received the FDA's Advanced Manufacturing Technology (AMT) designation. This recognition highlights its innovative design and potential impact. The system boasts a 100% automation success rate across numerous processes.
Scaling Production for Patient Needs
The science behind cell therapy is robust. The challenge lies in scaling production. Conventional methods are often manual and costly. They struggle to meet demand. Cellares addresses this bottleneck directly. Its automated platforms promise up to ten times more cell therapy batches. They achieve this at significantly reduced costs. This industrialization is crucial. It will unlock access for hundreds of thousands of patients.
Key Commercial and Clinical Validation
Cellares has achieved critical milestones. The company successfully manufactured and delivered GMP (Good Manufacturing Practice) doses of rese-cel. This is Cabaletta Bio’s investigational CAR T cell therapy. The doses met all specifications. They were infused into patients on schedule. This demonstrated clinical validation of the Cell Shuttle platform.
Following this success, Cabaletta Bio signed a 10-year commercial supply agreement. This secures future manufacturing capacity with Cellares. Another monumental agreement stands with Bristol Myers Squibb. This $380 million global manufacturing deal reserves significant capacity. It spans facilities in the United States, Europe, and Japan. These partnerships confirm Cellares' technical and commercial prowess. They validate its role as a preferred manufacturing partner.
Global Network of Smart Factories
Cellares is rapidly expanding its global footprint. It operates IDMO Smart Factories in South San Francisco, California. Another facility is in Bridgewater, New Jersey. Further expansion is underway. New facilities are under development in Leiden, the Netherlands. Another is planned for Kashiwa City, Japan. This global network is strategic. It ensures consistent production standards worldwide. It provides drug sponsors with localized manufacturing capabilities.
The Leiden facility is particularly significant for European expansion. It will be GMP-ready in 2027. Prime Radiant Partners’ expertise in European pharma services will aid this growth. The goal is a truly global manufacturing infrastructure. This network will support commercial-scale production for hundreds of thousands of patients annually. This target is set for 2027.
Future Prospects and Market Impact
The recent funding enables Cellares to accelerate its plans. The capital supports full commercial-scale operations. It also funds an anticipated Initial Public Offering (IPO) in 2027. This financial strategy positions Cellares for long-term growth. The company serves a range of cell therapy programs. These include CAR T, TCR-T, and progenitor T-cell therapies. Its partners include industry leaders like Bristol Myers Squibb and Cabaletta Bio. TScan Therapeutics and ProTgen also utilize Cellares platforms.
Cellares is transforming a specialized, complex process. It is making it industrial-scale, reliable, and affordable. This paradigm shift is essential for cell therapy's mainstream adoption. The company is building the infrastructure that modern medicine demands. Its vision of accessible, high-quality cell therapies is becoming reality. Cellares is a crucial player in the future of advanced therapeutic manufacturing. Its innovations promise to deliver life-saving treatments to a global patient population.